Skip to main content
Premium Trial:

Request an Annual Quote

Charles River, Proteome Systems Launch Joint Venture

NEW YORK, Oct. 2-Proteome Systems and Charles River Laboratories are launching a joint venture to provide contract-based proteomics testing and analysis services, the two companies said today.


The new service company will be known as Charles River Proteomics Services. It will use Proteome Systems' bioinformatics system, BioinformatIQ, and the company's proteomics platform, which includes protein separation, identification and characterization tools.


Charles River will own 80 percent of the joint venture, and Proteome Systems the remaining 20 percent, with an option to increase its position to 40 percent before March 2003. Charles River also has an option to purchase the entire company in January 2006.


The venture has been capitalized with $6 million in cash and loans from the two companies.


It will be located in Worcester, Massachusetts, in Charles River's drug discovery and development labs, and include space for automated sample handling machines, mass spectrometry hardware and computer systems. The 10,000-square-foot area will also be used as a demonstration facility for Proteome Systems to market its products.


Charles River Laboratories is a major provider of lab tools, supplies and services.


Proteome Systems develops technology for drug discovery and diagnostics., It is based in Sydney, Australia, with a US base in Woburn, Mass.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.